VOLOG

Dose: 0.10%
Single Dose: 0.1 (0.1)
Frequency: 8 hourly
Route: Topical
Instructions: -

Dose: 0.10%
Single Dose: 0.1 (0.1)
Frequency: 8 hourly
Route: Topical
Instructions: -

belongs to Corticosteroid. It belongs to Glucocorticoid agonist pharmacological group on the basis of mechanism of action and also classified in Dermatological Products and Corticosteroid Topical pharmacological group.The Molecular Weight of Halcinonide is 455.00.

Halcinonide is contraindicated in conditions like Varicella zoster infections.

The symptomatic adverse reactions produced by Halcinonide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Irritation, Itching, Burning, Acneform, Folliculitis, Striae, Hypopigmentation, Skin atrophy, Dryness, Hypertrichosis, Skin Atrophy, hypopigmentation.

Halcinonide is primarily indicated in conditions like Dermatitis, Inflammation.

No data regarding the interactions of Halcinonide was found.

ACTH Stimulation testUrinary free cortisol testACTH stimulation test

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Cream, Oint, Soln Do not Freeze. Protect from Sunlight.

Halcinonide should be used with caution in patients with active tuberculosis infection of respiratory tract or in untreated fungal, bacterial or systemic viral infections. Corticosteroids should only be used systemically with great caution in the presence of congestive heart failure (CHF), recent myocardial infraction (MI), hypertension, diabetes mellitus, epilepsy, glaucoma, hypothyroidism, liver failure, osteoporosis, peptic ulceration or renal impairment. Children may be at increase risk of some adverse effects, corticosteroid causes growth retardation and prolonged use is rarely justified. Passive immunization is recommended to non-immune patients who do come in contact with chickenpox or measles. Live vaccine should not be given to patients receiving high dose systemic corticosteroid therapy nor for atleast 3 months afterwards, killed vaccine or toxoids may be given, although the response may be attenuated. During prolong treatment with corticosteroids, patients should be examined regularly, sodium intake may need to be reduced and calcium and potassium supplement may be necessary. Patient should carry cards given full details of their corticosteroid therapy. Avoid use during pregnancy. Use nasal steroids with caution until healing has occurred.